AN2 Therapeutics, Inc. Quarterly Return On Equity in % from Q4 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
AN2 Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from Q4 2021 to Q3 2024.
  • AN2 Therapeutics, Inc. Return On Equity for the quarter ending September 30, 2024 was -57.6 %, a 2.32% increase year-over-year.
  • AN2 Therapeutics, Inc. annual Return On Equity for 2023 was -59.7 %, a 57.4% decline from 2022.
  • AN2 Therapeutics, Inc. annual Return On Equity for 2022 was -37.9 %, a 161% decline from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q3 2024 -57.6 +1.37 +2.32% Jul 1, 2024 Sep 30, 2024
Q2 2024 -54.7 +3.8 +6.49% Apr 1, 2024 Jun 30, 2024
Q1 2024 -57.2 -8.46 -17.4% Jan 1, 2024 Mar 31, 2024
Q4 2023 -59.7 -21.8 -57.4% Oct 1, 2023 Dec 31, 2023
Q3 2023 -59 -8.33 -16.4% Jul 1, 2023 Sep 30, 2023
Q2 2023 -58.5 +30.2 +34% Apr 1, 2023 Jun 30, 2023
Q1 2023 -48.7 -56.6K -100% Jan 1, 2023 Mar 31, 2023
Q4 2022 -37.9 -100 -161% Oct 1, 2022 Dec 31, 2022
Q3 2022 -50.7 Jul 1, 2022 Sep 30, 2022
Q2 2022 -88.7 Apr 1, 2022 Jun 30, 2022
Q1 2022 56.6K Jan 1, 2022 Mar 31, 2022
Q4 2021 62.1 Oct 1, 2021 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.